Table 1.
Clinical trials targeting ICD
| Conditions | NCT number | Trial title | Treatment | Phases | Enrollment |
|---|---|---|---|---|---|
| Metastatic colorectal cancer | NCT03186326 | Standard Chemotherapy vs Immunotherapy in 2nd Line Treatment of MSI Colorectal Metastatic Cancer | FOLFOX, FOLFIRI, Avelumab, Panitumumab, Cetuximab, Bevacizumab, Aflibercept | Phase 2 | 132 |
| NCT03388190 | METIMMOX: Colorectal Cancer METastasis – Shaping Anti tumor IMMunity by OXaliplatin | FLOX, Nivolumab | Phase 2 | 80 | |
| NCT03721653 | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | FOLFOXIRI, Bevacizumab, Atezolizumab | Phase 2 | 201 | |
| NCT04262687 | Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (POCHI) | Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab | Phase 2 | 55 | |
| Ovarian cancer | NCT01637532 | Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg Intron in Patients With Recurrent Ovarian Cancer | Carboplatin and caelyx or doxorubicin, Tocilizumab and interferon alpha 2-b | Phase 1/Phase 2 | 21 |
| NCT01666444 | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | VTX-2337, Pegylated liposomal doxorubicin | Phase 2 | 297 | |
| NCT04072263 | Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer | Tumor-infiltrating lymphocytes, Interferon alfa 2A, Carboplatin, Paclitaxel | Phase 1/Phase 2 | 12 | |
| Breast cancer | NCT03164993 | Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple negative Breast Cancer | Atezolizumab, Pegylated liposomal doxorubicin, Cyclophosphamide | Phase 2 | 75 |
| NCT03409198 | Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer | Ipilimumab, Nivolumab, Pegylated liposomal doxorubicin, Cyclophosphamide | Phase 2 | 82 | |
| Endometrial cancer | NCT03276013 | Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer | Doxorubicin, Pembrolizumab | Phase 2 | 48 |
| B-cell lymphoma | NCT03321643 | Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma | Atezolizumab, Gemcitabine, Oxaliplatin, Rituximab | Phase 1 | 24 |
| Non-small cell lung cancer | NCT04043195 | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC | Oxaliplatin, Nivolumab, Ipilimumab | Phase 1/Phase 2 | 30 |
| Uveal melanoma | NCT04463368 | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases | Melphalan, Ipilimumab, Nivolumab | Phase 1 | 18 |